Connecticut Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Connecticut Health Digest.

Press releases published on July 7, 2026

Jul. 7, 2026

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Indeterminate GlobeNewswire

Jul. 7, 2026

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

Indeterminate GlobeNewswire

Jul. 7, 2026

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Indeterminate GlobeNewswire

Jul. 7, 2026

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Indeterminate GlobeNewswire

Jul. 7, 2026

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Indeterminate GlobeNewswire

Jul. 7, 2026

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Indeterminate GlobeNewswire

Jul. 7, 2026

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Indeterminate GlobeNewswire

Jul. 7, 2026

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

Indeterminate GlobeNewswire

Jul. 7, 2026

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

Indeterminate GlobeNewswire

Jul. 7, 2026

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

Indeterminate GlobeNewswire

Jul. 7, 2026

ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs

Indeterminate GlobeNewswire

Jul. 7, 2026

Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis

Indeterminate GlobeNewswire

Jul. 7, 2026

Rapid Nutrition Showcases HealthTech Strategy on Bloomberg Television

Indeterminate GlobeNewswire